PAS: Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants

Sponsor
Vermont Oxford Network (Other)
Overall Status
Completed
CT.gov ID
NCT01164124
Collaborator
University of Vermont (Other), St. Louis University (Other), Cardinal Glennon Children's Hospital (Other), Saint John Hospital & Medical Center (Other)
101
3
2
18
33.7
1.9

Study Details

Study Description

Brief Summary

The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
  • Other: Placebo
Phase 2/Phase 3

Detailed Description

The overall purpose of this research is to test whether adding a supplement to the feeding of extremely low birth weight infant (infants weighing less than 2 pound 2 oz at birth) will help him/her achieve full feeding faster and achieve better weight gain. The study also will evaluate the benefit of that feeding supplement in decreasing the rate of infection (in the blood or in the urine) and antibiotics use in those infants.

When babies are born, the digestive system (the gastrointestinal tract) is sterile. There are no bacteria residing in their gut. When babies start feeding, it is normal for the intestine to start growing several types of bacteria. These normal (good) bacteria are thought to be helpful in keeping the intestine healthy. This is not the case in premature infants. It takes premature infants a longer time to grow bacteria in their intestines and they have fewer numbers of bacteria. In addition, the bacteria premature infants grow are not the normal one that we see in healthy infants. Instead they grow unhealthy (bad) bacteria that can potentially play a role in causing infection in the blood and urine.

Adding the normal (good) bacteria to the breast milk or infant formula might help to protect premature babies from developing blood or urine infection. In addition, adding the good bacteria might be beneficial in terms of better tolerance to milk feeding. As a result, babies may have less episodes of feeding holding and have better weight gain. Two species of bacteria, called Lactobacillus and Bifidobacteria, have been used to study this in other studies of premature babies. These two species are the most plentiful bacteria seen in the bowels of full term babies.

Participation in the study involves enrolling premature babies to receive supplement to the feeding when he/she ready to feed. Babies will be randomly assigned to receive either a bacteria (probiotic) supplement or be fed without supplement. The supplement will be added to one feeding each day. Enrolled babies will continue to get the supplement for 6-10 week. Other than the feeding supplement, being in this study will not affect care.

The main outcomes of the study will be feeding tolerance and growth. Other complications associated with prematurity, on particular infection of either the gastrointestinal tract or the blood stream will be evaluated.

Study Design

Study Type:
Interventional
Actual Enrollment :
101 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants
Study Start Date :
Feb 1, 2008
Actual Primary Completion Date :
May 1, 2009
Actual Study Completion Date :
Aug 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: Probiotic supplementation

500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)

Dietary Supplement: Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)
The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)

Placebo Comparator: Routine feedings

Other: Placebo
routine feedings

Outcome Measures

Primary Outcome Measures

  1. Growth [34 weeks postmenstrual age]

    Percentage of infants with weight less than the 10th percentile at 34 weeks postmenstrual age.

  2. Growth [28 days from study entry]

    Average weight gain and growth velocity during the first 28 days from initiation of feeding.

  3. Feeding Tolerance [28 days from study entry]

    Volume of feeding per day during the first 28 days from the initiation of feeding.

Secondary Outcome Measures

  1. Antimicrobial therapy [34 weeks post menstrual age]

    Days of antimicrobial treatment until 34 weeks post menstrual age.

  2. Complications of prematurity [until hospital discharge]

    common complications of prematurity including but not limited to sepsis, necrotizing enterocolitis, and mortality.

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 14 Days
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • birth weight less than or equal to 1000 grams,

  • appropriately grown for gestational age,

  • age 1 to 14 days inclusive,

  • intention to start enteral feeds,

  • written informed consent obtained

Exclusion Criteria:
  • known life-threatening congenital anomaly or condition affecting

  • gastrointestinal function,

  • previous NEC or gastrointestinal perforation,

  • previous supplementation with probiotics

  • previous enteral feedings

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. John Hospital & Medical Center Detroit Michigan United States 48236
2 Cardinal Glennon Children's Hospital Saint Louis Missouri United States 63104-1095
3 VT Children's at Fletcher-Allen Health Care Burlington Vermont United States 05401

Sponsors and Collaborators

  • Vermont Oxford Network
  • University of Vermont
  • St. Louis University
  • Cardinal Glennon Children's Hospital
  • Saint John Hospital & Medical Center

Investigators

  • Principal Investigator: Mohamad Al-Hosni, MD, St. Louis University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Vermont Oxford Network
ClinicalTrials.gov Identifier:
NCT01164124
Other Study ID Numbers:
  • CHRMS 08-019
First Posted:
Jul 16, 2010
Last Update Posted:
Jul 2, 2018
Last Verified:
Jun 1, 2018

Study Results

No Results Posted as of Jul 2, 2018